SCHEMBL21025832

SCHEMBL21025832

CC(C)c1cnc(C(C)(C)c2nccnn2)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21673477 0.80
SCHEMBL20155648 0.75
SCHEMBL1702353 0.72 HMGCR (0.30)
SCHEMBL24026540 0.70 SMN1; SMN2 (0.39)
SCHEMBL20696793 0.69 ALOX5AP (0.31)
SCHEMBL18068056 0.69 CYP3A4 (0.34)
SCHEMBL25996323 0.69
SCHEMBL12197725 0.66 CYP3A4 (0.43)
SCHEMBL5950443 0.66 NOS3 (0.33)
SCHEMBL15457960 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2021-07-20 US disclosed
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2019-10-03 US disclosed
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES ARVINAS OPERATIONS, INC. 2019-05-23 US disclosed